

PATRICK J. LEAHY, VERMONT, CHAIRMAN

HERB KOHL, WISCONSIN
DIANNE FEINSTEIN, CALIFORNIA
CHARLES E. SCHUMER, NEW YORK
RICHARD J. DURBIN, ILLINOIS
SHELDON WHITEHOUSE, RHODE ISLAND
AMY KLOBUCHAR, MINNESOTA
AL FRANKEN, MINNESOTA
CHRISTOPHER A. COONS, DELAWARE
RICHARD BLUMENTHAL, CONNECTICUT

CHARLES E. GRASSLEY, IOWA
ORRIN G. HATCH, UTAH
JON KYL, ARIZONA
JEFF SESSIONS, ALABAMA
LINDSEY O. GRAHAM, SOUTH CAROLINA
JOHN CORNYN, TEXAS
MICHAEL S. LEE, UTAH
TOM COBURN, OKLAHOMA

United States Senate

COMMITTEE ON THE JUDICIARY
WASHINGTON, DC 20510-6275

BRUCE A. COHEN, *Chief Counsel and Staff Director*
KOLAN L. DAVIS, *Republican Chief Counsel and Staff Director*

May 4, 2011

Via Electronic Transmission

John Feather, CAE, CFRE
Executive Director and Chief Executive Officer
American Society of Consultant Pharmacists
1321 Duke Street
Alexandria, VA 22314

Dear Mr. Feather:

In December 2009, I asked for an accounting of industry funding that the American Society of Consultant Pharmacists (ASCP) receives from pharmaceutical and medical device companies as well as foundations established by these companies or the insurance industry. I appreciate your response, which I have attached to this letter. I write today to follow up on any efforts by your organization to improve transparency and accountability in its relationships with the pharmaceutical and device industries.

As I stated in my previous letter, I started my inquiry, in part, as a result of accounts documenting the lack of transparency in financial relationships between the pharmaceutical industry and nonprofit health and medical organizations. Specifically, I cited the April 2008 article in *The Wall Street Journal*, which reported that industry representatives, including ten major drug companies, had formed a coalition to promote looser restrictions on off-label marketing.¹ The coalition had asked the National Alliance on Mental Illness (NAMI) to speak in favor of this issue.

In response to my concerns in my April 2009 letter to NAMI, NAMI began to voluntarily disclose to the public any amount of funding exceeding \$5,000 that it received from pharmaceutical companies and foundations on its website. Further, NAMI began to provide a brief description of the purpose of the funding on its website. I commend NAMI for its leadership and had hoped that when I reached out to your organization and 32 others, your organization would follow NAMI's example and begin posting similar funding information on ASCP's website.

As of the date of this letter, it appears that your organization has taken steps to identify on its website the corporate or industry sponsors and their range of funding support. However, the website does not specify the purposes of that funding. If ASCP is currently taking steps to

¹ Alicia Mundy, "Off-Label Use of Drugs Gets a Push --- Big Pharma Lobbies Washington to Relax Rules on Marketing," *The Wall Street Journal*, April 18, 2008.

further enhance the transparency of its financial relationships with the pharmaceutical and device industries, I would appreciate information regarding those steps. In particular, please state whether or not ASCP will be adding information in the future about the purpose of the funding it receives. If not, please explain why not.

The Medicare Payment Advisory Commission (MedPAC) recommended in a report to Congress in March 2009 that Congress require that pharmaceutical and device companies report their financial relationships with physician groups, patient organizations, and others. More specifically MedPAC said the following:

Given the potential benefits of public reporting, we recommend that the Congress mandate the reporting of comprehensive information on industry relationships with physicians and other health care entities and that the Secretary post this information on a public searchable website.²

MedPAC then went on to say in Recommendation 5-1 that:

The Congress should require all manufacturers and distributors of drugs, biologicals, medical devices, and medical supplies (and their subsidiaries) to report to the Secretary their financial relationship with: . . . physician groups and other prescribers . . . patient organizations; and professional organizations.³

I look forward to working with you and other health and medical organizations to further increase sunshine on financial relationships.

Thank you for your cooperation and attention in this matter. I would appreciate a response by May 25, 2011. If you have any questions, please do not hesitate to contact Brian Downey for the Committee on the Judiciary at (202) 224-5225.

Sincerely,



Charles E. Grassley
Ranking Member

Attachments

² Medicare Payment Advisory Commission, "Public reporting of physicians' financial relationships," Report to Congress: Medicare Payment Policy, March 2009.

³ *Id.*

Attachment



AMERICAN SOCIETY OF **CONSULTANT PHARMACISTS**

December 21, 2009

Via Electronic Transmission

The Honorable Charles E. Grassley
Ranking Member
Committee on Finance
United States Senate
Washington, DC 20510-6200

Dear Sen. Grassley:

On behalf of the American Society of Consultant Pharmacists (ASCP), I am responding to your letter of December 7, 2009, requesting information on "industry funding that pharmaceutical, medical device companies, foundations established by these companies or the insurance industry have provided to ASCP" for the period of January 2006 to the present. The material requested is provided in attachments to this letter.

ASCP is a professional association of pharmacists who specialize in the care of the elderly, and as such, we are particularly sensitive to the need provide accurate and unbiased information to our members. We have a forty year history of rigorously following the highest level of standards to ensure that all educational content is under our complete control, whether the particular educational program receives outside support or not. Our credibility as a professional organization could not be preserved if we did otherwise.

In particular, we carefully follow the detailed standards required by the Accreditation Council for Pharmacy Education (ACPE), an autonomous and independent agency for the accreditation of professional degree programs in pharmacy and providers of continuing pharmacy education. ACPE was established in 1932 for the accreditation of pre-service education, and in 1975 its scope of activity was broadened to include accreditation of providers of continuing pharmacy education (see <http://www.acpe-accredit.org> for complete information).

ACPE's Accreditation Standards for Continuing Pharmacy Education (attached to this letter or at http://www.acpe-accredit.org/pdf/CPE_Standards_Final.pdf) provides extensive guidance on the issue in Standard 5: Standards for Commercial Support and Appendix II, including:

1321 Duke Street
Alexandria, VA 22314-3563
703/739-1300
703/739-1321fax
info@ascp.com
<http://www.ascp.com/>

America's Senior Care Pharmacists™



The provider must plan all CPE [Continuing Pharmacy Education] activities independent of commercial interest. The educational content must be presented with full disclosure and equitable balance. Appropriate topics and learning activities must be distinguished from topics and learning activities which are promotional or appear to be intended for the purpose of endorsing either a specific commercial drug, device or other commercial product (as contrasted with the generic product/drug entity and its contents or the general therapeutic area it addresses), or a specific commercial service (as contrasted with the general service area and/or the aspects or problems of professional practice it addresses).

ASCP is a major provider of continuing education in geriatric pharmacy and is subject to periodic review by ACPE of our policies, procedures, and practices. We are proud that ACPE's most recent rigorous review in 2008, which included a random review of specific CPE programs, gave us the highest rating available and allowed us to continue to provide professional education under these standards for an additional six years.

In keeping with the ACPE standards, we do provide opportunities for our members to learn more about specific products, but in all circumstances, these activities are clearly and carefully labeled as promotional in nature and must meet the strict regulatory requirements established by the Food and Drug Administration as to the content and disclosures that must be used.

Additionally, to maintain our credibility as a provider of education and information, ASCP also has taken a number of steps to increase the transparency of our relationship to industry sponsors, including:

- Acknowledging support of programs if they are supported by industry. If any programs or activities are funded using industry support, they are publically identified as the supporter of the program in both printed materials and to the audience if it is an in person event.
- Providing detailed financial information on industry support to our Board.
- Developing a policy and process to list industry support on our website. We anticipate that this policy and process will be implemented sometime next year.

As requested, we have used the charts attached to this letter to provide the detailed information you requested for the years 2006-2009, as well as providing our policies on the issues requested.

Please feel free to contact me directly at jfeather@ascp.com or 703-739-1316 ext. 300 if I clarify any of this information. Thank you for your continuing commitment to the health of Medicare and Medicaid beneficiaries.

Sincerely,

A handwritten signature in black ink, appearing to read "John Feather". The signature is fluid and cursive, with the first name "John" and last name "Feather" clearly distinguishable.

John Feather, PhD, CAE
Executive Director and CEO



AMERICAN SOCIETY OF **CONSULTANT PHARMACISTS**

American Society of Consultant Pharmacists

Responses to the United States Senate Committee on Finance

I. Accounting of Industry Funding by Year (Tab 1)

II. ASCP Policies for Accepting Industry Funding (Tab 2)

Q1. Please describe the policies for accepting industry funding and whether or not ASCP allows companies to place restrictions or provide guidance on how funding will be spent.

A1. As a major provider of continuing education in geriatric pharmacy, ASCP is accredited by the Accreditation Council for Pharmacy Education (ACPE), an autonomous and independent agency for the accreditation of professional degree programs in pharmacy and providers of continuing pharmacy education. ACPE was established in 1932 for the accreditation of pre-service education, and in 1975 its scope of activity was broadened to include accreditation of providers of continuing pharmacy education (see <http://www.acpe-accredit.org> for complete information).

ASCP carefully follows ACPE's detailed standards and in keeping with those standards, we maintain full control over educational content and do not allow companies to place restrictions or provide guidance on how funding will be spent.

ACPE renewed ASCP's status as an accredited provider of continuing pharmacy education (CPE) in January 2008 after a complete review of our policies, procedures and practices. The current accreditation term extends for six years until January 31, 2014. ACPE's report regarding ASCP is attached for your review, as well as other documents noted below. In response to recommendations made by ACPE at the time of its review, ASCP is in the process of updating its Policies and Procedures for CPE. ASCP's current "Policies and Procedures" as well as a draft containing the proposed changes to the existing "Policies and Procedures," have been produced. The draft changes are currently under review by ASCP's Board of Directors and will be considered at the next Board of Director's meeting, scheduled for May 24-25, 2010.

1321 Duke Street
Alexandria, VA 22314-3563
703/739-1300
703/739-1321fax
info@ascp.com
<http://www.ascp.com/>

America's Senior Care Pharmacists™



Documents Produced

- 1) ASCP Policies and Procedures for Continuing Pharmaceutical Education
- 2) ASCP Policies and Procedures for Continuing Pharmaceutical Education – Draft for Review and Comment, 12-10-09
- 3) ACPE Letter to Patricia D'Antonio, Director of Educational Affairs, ASCP and ACPE Accreditation Action and Recommendations After Review of a Petition for Continued Accreditation, January 2008
- 4) ASCP's ACPE Certificate of Accreditation, January 31, 2008
- 5) Accreditation Council for Pharmacy Education, Accreditation Standards for Continuing Pharmacy Education, effective January 1, 2009
- 6) ACPE, Standard 5: Standards for Commercial Support (SCS)
- 7) ACPE Accreditation Standards for Continuing Pharmacy Education (CPE) Guidelines for Standards for Commercial Support – CPE Standard 5, August 2008

Q.2. If ASCP allows companies to place restrictions on industry funding, then please explain all restrictions and/or guidance for each transfer of value from industry. For every transfer of value with a restriction, please provide the following information: year of transfer, name of company, and restriction placed on funding.

A.2. NA – See Answer 1 above.

Q.3. Please explain what policies, if any that ASCP plans to adopt to ensure transparency of funding in order to provide a greater public trust in the independence of your organization.

A.3. ASCP enjoys a reputation as a trusted source of information regarding the appropriate, safe and effective use of medicines in the elderly. Our reputation is based upon a 40-year track record of promoting high standards of professionalism and excellence in clinical practice. In addition to the policies noted above, ASCP has taken a number of steps to increase the transparency of our relationship to industry sponsors, including:

- If any programs or activities are funded using industry support, they are publically identified as the supporter of the program in both printed materials and to the audience if it is an in person event.
- Detailed financial information on industry support is provided to the Executive Committee of the Board on a monthly basis and to the full Board at every meeting. A complete report of industry support is compiled on an annual basis.

- All industry-supported activities that are promotional in nature are clearly labeled as such and all promotional materials must comply strictly with the Food and Drug Administration in terms of the information provided either in print or in person at exhibits.
- We are in the process of developing and implementing a policy to list industry support on our website.

Q.4. Please explain your policies on disclosure of outside income by your top executives and board members.

A.4. ASCP's written policies prohibit employees from entering into relationships with persons or organizations in any activity directly or indirectly detrimental to ASCP or where compensation is contingent on a result of the individual's employment with ASCP. All employees must acknowledge that they have read and are familiar with the details of this policy and must disclose any interests (outside employment or compensation) on an annual basis. If any outside employment or compensation arrangement presents a conflict of interest, ASCP's policies require that it be minimized or eliminated.

ASCP's written policies also require that Board Members disclose all potential conflicts of interest in employment, professional activities and financial interests on an annual basis. In the event a Board Member is involved in activities or organizations that constitute an actual conflict of interest that affects his/her continued service, he/she must take prompt action to resolve the conflict by (a) terminating the conflicting activity or organizational affiliation; or (b) by resigning from the ASCP Board of Directors.

In addition, ASCP files a detailed tax form (IRS Form 990) that contains a great deal of detailed financial information on payments made to senior staff and members of the Board of Directors.

Documents Produced:

- 1) ASCP Employee Conflicts of Interest Policy
- 2) ASCP Disclosure of Bias or Potential Conflicts of Interest and Related Party Transactions

Q.5. Please provide the disclosures of outside income filed with your organization by your top executives and Board Members.

Documents produced:

- 1) ASCP Employee Conflicts of Interest Disclosures filed by Current executive staff
- 2) ASCP Board of Directors Disclosure Statements

**American Society of Consultant Pharmacists
2006 Funding by Support Type**

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|---|------------------------------|-----------------|------------------------|------------------|
| Commercial Support | | | | |
| Bimark Medical Communications | Medical Education Companies | \$ 6,500 | \$ - | \$ 6,500 |
| Gladson Design Group | Medical Education Companies | \$ 3,000 | \$ - | \$ 3,000 |
| MatureHealth Communications | Medical Education Companies | \$ 800 | \$ - | \$ 800 |
| MRCGROUP Research Institute | Medical Education Companies | \$ 2,150 | \$ - | \$ 2,150 |
| Precept Educational Sciences | Medical Education Companies | \$ 3,500 | \$ - | \$ 3,500 |
| ProCom | Medical Education Companies | \$ 3,500 | \$ - | \$ 3,500 |
| The CE Solution | Medical Education Companies | \$ 3,150 | \$ - | \$ 3,150 |
| Diagnostic Devices, Inc. | Medical Equipment and Device | \$ 3,150 | \$ - | \$ 3,150 |
| Roche Diagnostics | Medical Equipment and Device | \$ 3,150 | \$ - | \$ 3,150 |
| Abbott Laboratories | Pharmaceutical Manufacturer | \$ 52,815 | \$ - | \$ 52,815 |
| Alpharma Branded Products Division Inc. | Pharmaceutical Manufacturer | \$ 12,000 | \$ - | \$ 12,000 |
| Amgen Inc. | Pharmaceutical Manufacturer | \$ 42,250 | \$ - | \$ 42,250 |
| Anda, Inc. | Pharmaceutical Manufacturer | \$ 22,125 | \$ - | \$ 22,125 |
| Apotex Corp | Pharmaceutical Manufacturer | \$ 3,150 | \$ - | \$ 3,150 |
| Astellas Pharma US | Pharmaceutical Manufacturer | \$ 1,811 | \$ - | \$ 1,811 |
| AstraZeneca Pharmaceuticals LP | Pharmaceutical Manufacturer | \$ 68,775 | \$ - | \$ 68,775 |
| Biovail Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 5,300 | \$ - | \$ 5,300 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 70,377 | \$ - | \$ 70,377 |
| Bristol-Myers Squibb Company | Pharmaceutical Manufacturer | \$ 206,006 | \$ - | \$ 206,006 |
| Cephalon, Inc. | Pharmaceutical Manufacturer | \$ 3,000 | \$ - | \$ 3,000 |
| DermaRite Industries | Pharmaceutical Manufacturer | \$ 11,300 | \$ - | \$ 11,300 |
| Dey, L.P. | Pharmaceutical Manufacturer | \$ 11,300 | \$ - | \$ 11,300 |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 46,577 | \$ - | \$ 46,577 |
| Eli Lilly and Company | Pharmaceutical Manufacturer | \$ 15,750 | \$ - | \$ 15,750 |
| Esprit Pharma, Inc. | Pharmaceutical Manufacturer | \$ 9,050 | \$ - | \$ 9,050 |
| ETHEX Corporation | Pharmaceutical Manufacturer | \$ 3,150 | \$ - | \$ 3,150 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 205,150 | \$ - | \$ 205,150 |
| G & W Laboratories | Pharmaceutical Manufacturer | \$ 3,000 | \$ - | \$ 3,000 |
| Genetco, Inc | Pharmaceutical Manufacturer | \$ 3,150 | \$ - | \$ 3,150 |
| Geritrex Corporation | Pharmaceutical Manufacturer | \$ 3,150 | \$ - | \$ 3,150 |
| GlaxoSmithKline | Pharmaceutical Manufacturer | \$ 60,060 | \$ - | \$ 60,060 |
| Healthpoint, Ltd. | Pharmaceutical Manufacturer | \$ 5,300 | \$ - | \$ 5,300 |
| Hi-Tech Pharmacal | Pharmaceutical Manufacturer | \$ 7,727 | \$ - | \$ 7,727 |
| Janssen Pharmaceutica | Pharmaceutical Manufacturer | \$ 62,118 | \$ - | \$ 62,118 |
| Johnson & Johnson Health Care Systems, Inc. | Pharmaceutical Manufacturer | \$ 137,042 | \$ - | \$ 137,042 |
| Ligand Pharmaceuticals | Pharmaceutical Manufacturer | \$ 5,150 | \$ - | \$ 5,150 |
| Mallinckrodt, Inc. | Pharmaceutical Manufacturer | \$ 9,050 | \$ - | \$ 9,050 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 17,900 | \$ - | \$ 17,900 |
| Merck Schering Plough | Pharmaceutical Manufacturer | \$ 8,100 | \$ - | \$ 8,100 |
| Mission Pharmacal Company | Pharmaceutical Manufacturer | \$ 3,150 | \$ - | \$ 3,150 |
| Mylan Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 44,472 | \$ - | \$ 44,472 |
| Novartis Pharmaceuticals Corporation | Pharmaceutical Manufacturer | \$ 4,400 | \$ - | \$ 4,400 |
| Novo Nordisk Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 11,302 | \$ - | \$ 11,302 |
| Nuvite Labs | Pharmaceutical Manufacturer | \$ 3,000 | \$ - | \$ 3,000 |
| Ortho Biotech Product, L.P. | Pharmaceutical Manufacturer | \$ 26,251 | \$ - | \$ 26,251 |
| Ortho-McNeil Pharmaceuticals | Pharmaceutical Manufacturer | \$ 46,004 | \$ - | \$ 46,004 |
| Oscient Pharmaceuticals Corp. | Pharmaceutical Manufacturer | \$ 2,150 | \$ - | \$ 2,150 |
| Otsuka America Pharmaceutical, Inc. | Pharmaceutical Manufacturer | \$ 8,000 | \$ - | \$ 8,000 |
| Paddock Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 5,300 | \$ - | \$ 5,300 |

**American Society of Consultant Pharmacists
2006 Funding by Support Type**

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|--|-----------------------------|-----------------|------------------------|------------------|
| PAR Pharmaceutical | Pharmaceutical Manufacturer | \$ 9,150 | \$ - | \$ 9,150 |
| Pfizer Inc. | Pharmaceutical Manufacturer | \$ 167,288 | \$ - | \$ 167,288 |
| Prasco Laboratories | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Procter & Gamble Pharmaceuticals | Pharmaceutical Manufacturer | \$ 8,800 | \$ - | \$ 8,800 |
| QCE Laboratories | Pharmaceutical Manufacturer | \$ 3,000 | \$ - | \$ 3,000 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 61,900 | \$ - | \$ 61,900 |
| SANTARUS, Inc. | Pharmaceutical Manufacturer | \$ 5,150 | \$ - | \$ 5,150 |
| Schwarz Pharma, Inc. | Pharmaceutical Manufacturer | \$ 5,300 | \$ - | \$ 5,300 |
| Sepracor, Inc. | Pharmaceutical Manufacturer | \$ 1,950 | \$ - | \$ 1,950 |
| Solvay Pharmaceuticals | Pharmaceutical Manufacturer | \$ 14,000 | \$ - | \$ 14,000 |
| Sucampo Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 15,750 | \$ - | \$ 15,750 |
| Takeda Pharmaceuticals North America, Inc. | Pharmaceutical Manufacturer | \$ 30,500 | \$ - | \$ 30,500 |
| TAP Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 25,550 | \$ - | \$ 25,550 |
| Taro Pharmaceuticals | Pharmaceutical Manufacturer | \$ 3,000 | \$ - | \$ 3,000 |
| Teva Pharmaceuticals USA | Pharmaceutical Manufacturer | \$ 7,400 | \$ - | \$ 7,400 |
| Ther-Rx Corporation | Pharmaceutical Manufacturer | \$ 6,450 | \$ - | \$ 6,450 |
| UCB Pharma, Inc. | Pharmaceutical Manufacturer | \$ 14,000 | \$ - | \$ 14,000 |
| UDL Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 7,250 | \$ - | \$ 7,250 |
| Upsher-Smith Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 3,150 | \$ - | \$ 3,150 |
| Watson Pharma, Inc. | Pharmaceutical Manufacturer | \$ 11,700 | \$ - | \$ 11,700 |
| Wyeth | Pharmaceutical Manufacturer | \$ 16,890 | \$ - | \$ 16,890 |

| | | | | |
|---------------------------------|--|--------------------|------------|--------------------|
| Total Commercial Support | | \$1,714,740 | \$0 | \$1,714,740 |
|---------------------------------|--|--------------------|------------|--------------------|

| | | | | |
|---|-----------------------------|------------|------------|------------|
| Educational Support | | | | |
| Medical Communications Media, Inc. | Medical Education Company | \$ 82,000 | \$ - | \$ 82,000 |
| Abbott Laboratories | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| Amgen Inc. | Pharmaceutical Manufacturer | \$ 238,425 | \$ - | \$ 238,425 |
| Astellas Pharma US | Pharmaceutical Manufacturer | \$ 11,000 | \$ - | \$ 11,000 |
| AstraZeneca Pharmaceuticals LP | Pharmaceutical Manufacturer | \$ 30,000 | \$ - | \$ 30,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 37,000 | \$ - | \$ 37,000 |
| Bristol-Myers Squibb Company | Pharmaceutical Manufacturer | \$ 159,270 | \$ - | \$ 159,270 |
| Dey L.P. | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| GlaxoSmithKline | Pharmaceutical Manufacturer | \$ 55,000 | \$ - | \$ 55,000 |
| Johnson & Johnson Health Care Systems, Inc. | Pharmaceutical Manufacturer | \$ 60,000 | \$ - | \$ 60,000 |
| Mallinckrodt, Inc. | Pharmaceutical Manufacturer | \$ 5,000 | \$ - | \$ 5,000 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 192,300 | \$ 84,300 | \$ 108,000 |
| Novartis Pharmaceuticals Corporation | Pharmaceutical Manufacturer | \$ 18,000 | \$ - | \$ 18,000 |
| Novo Nordisk Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 144,643 | \$ 122,643 | \$ 22,000 |
| Ortho Biotech Product, L.P. | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| Ortho-McNeil Pharmaceuticals | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| PAR Pharmaceutical | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| Pfizer Inc. | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 153,970 | \$ - | \$ 153,970 |
| Sucampo Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 11,000 | \$ - | \$ 11,000 |
| Takeda Pharmaceuticals North America, Inc. | Pharmaceutical Manufacturer | \$ 162,000 | \$ - | \$ 162,000 |
| TAP Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| Watson Pharma, Inc. | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |

**American Society of Consultant Pharmacists
2006 Funding by Support Type**

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|--------------|--------------|-----------------|------------------------|------------------|
|--------------|--------------|-----------------|------------------------|------------------|

| | | | | |
|----------------------------------|--|--------------------|------------------|--------------------|
| Total Educational Support | | \$1,557,608 | \$206,943 | \$1,350,665 |
|----------------------------------|--|--------------------|------------------|--------------------|

| | | | | |
|--|-----------------------------|-----------|----------|-----------|
| General Sponsorship Support | | | | |
| Amgen Inc. | Pharmaceutical Manufacturer | \$ 35,000 | \$ - | \$ 35,000 |
| AstraZeneca Pharmaceuticals | Pharmaceutical Manufacturer | \$ 5,000 | \$ - | \$ 5,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 60,000 | \$ - | \$ 60,000 |
| Eisai Inc. | Pharmaceutical Manufacturer | \$ 55,000 | \$ - | \$ 55,000 |
| Esprit Pharma, Inc. | Pharmaceutical Manufacturer | \$ 5,000 | \$ - | \$ 5,000 |
| Mallinckrodt, Inc. | Pharmaceutical Manufacturer | \$ 10,000 | \$ - | \$ 10,000 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 7,000 | \$ - | \$ 7,000 |
| Novartis Pharmaceuticals Corporation | Pharmaceutical Manufacturer | \$ 15,000 | \$ - | \$ 15,000 |
| Otsuka America Pharmaceutical, Inc. | Pharmaceutical Manufacturer | \$ 5,000 | \$ - | \$ 5,000 |
| Procter & Gamble Pharmaceuticals | Pharmaceutical Manufacturer | \$ 4,500 | \$ 4,050 | \$ 450 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 62,500 | \$ - | \$ 62,500 |
| Sepracor, Inc. | Pharmaceutical Manufacturer | \$ 5,000 | \$ - | \$ 5,000 |

| | | | | |
|--|--|------------------|----------------|------------------|
| Total General Sponsorship Support | | \$269,000 | \$4,050 | \$264,950 |
|--|--|------------------|----------------|------------------|

| | | | | |
|--|-----------------------------|-----------|------|-----------|
| Consulting Support | | | | |
| Takeda Pharmaceuticals North America, Inc. | Pharmaceutical Manufacturer | \$ 60,000 | \$ - | \$ 60,000 |

| | | | | |
|---------------------------------|--|-----------------|------------|-----------------|
| Total Consulting Support | | \$60,000 | \$0 | \$60,000 |
|---------------------------------|--|-----------------|------------|-----------------|

| | | | | |
|--|------------------------------|----------|------|----------|
| Dues | | | | |
| Apothecary Products, Inc. | Medical Equipment and Device | \$ 2,000 | \$ - | \$ 2,000 |
| Abbott Laboratories | Pharmaceutical Manufacturer | | \$ - | \$ - |
| Amgen | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| AstraZeneca Pharmaceuticals LP | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Eli Lilly and Company | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Esprit Pharma, Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| GlaxoSmithKline | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| IVAX Pharmaceuticals | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| King Pharmaceuticals | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Mallinckrodt, Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| McKesson | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Organon Pharmaceuticals USA Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Otsuka America Pharmaceutical Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Par Pharmaceuticals Companies, Inc. | Pharmaceutical Manufacturer | \$ 2,200 | \$ - | \$ 2,200 |
| Pfizer Inc. | Pharmaceutical Manufacturer | \$ 2,200 | \$ - | \$ 2,200 |
| Procter & Gamble Pharmaceuticals | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Purdue Pharma L.P. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| The Long Term Group: Johnson & Johnson Health Care | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| UCB Pharma, Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| UDL Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Wyeth | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |

American Society of Consultant Pharmacists
2006 Funding by Support Type

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|----------------------|--------------|--------------------|------------------------|--------------------|
| <i>Total Dues</i> | | <i>\$50,400</i> | <i>\$0</i> | <i>\$50,400</i> |
| TOTAL SUPPORT | | \$3,651,747 | \$210,993 | \$3,440,755 |

* ASCP was prime recipient of grant funds and payments were made to third-party partners as part of contractual obligation.

**American Society of Consultant Pharmacists
2007 Funding by Support Type**

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|---|------------------------------|-----------------|------------------------|------------------|
| Commercial Support | | | | |
| Academy for HealthCare | Medical Education Company | \$ 3,145 | \$ - | \$ 3,145 |
| Advanced Concepts Institute | Medical Education Company | \$ 1,883 | \$ - | \$ 1,883 |
| HRA Research | Medical Education Company | \$ 3,500 | \$ - | \$ 3,500 |
| MatureHealth Communications | Medical Education Company | \$ 1,590 | \$ - | \$ 1,590 |
| Accu - flo by Creative Strategies | Medical Equipment and Device | \$ 3,950 | \$ - | \$ 3,950 |
| Roche Diagnostics | Medical Equipment and Device | \$ 3,650 | \$ - | \$ 3,650 |
| Abbott Laboratories | Pharmaceutical Manufacturer | \$ 22,350 | \$ - | \$ 22,350 |
| Allergan, Inc. | Pharmaceutical Manufacturer | \$ 6,350 | \$ - | \$ 6,350 |
| Alpharma Branded Products Division Inc. | Pharmaceutical Manufacturer | \$ 1,800 | \$ - | \$ 1,800 |
| Amgen | Pharmaceutical Manufacturer | \$ 21,550 | \$ - | \$ 21,550 |
| Anda, Inc. | Pharmaceutical Manufacturer | \$ 25,250 | \$ - | \$ 25,250 |
| Apotex Corp | Pharmaceutical Manufacturer | \$ 3,650 | \$ - | \$ 3,650 |
| AstraZeneca Pharmaceuticals LP | Pharmaceutical Manufacturer | \$ 54,350 | \$ - | \$ 54,350 |
| Biocodex Inc. | Pharmaceutical Manufacturer | \$ 6,100 | \$ - | \$ 6,100 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 126,850 | \$ - | \$ 126,850 |
| Breckenridge Pharmaceutical, Inc. | Pharmaceutical Manufacturer | \$ 5,800 | \$ - | \$ 5,800 |
| Bristol-Myers Squibb Company | Pharmaceutical Manufacturer | \$ 171,794 | \$ - | \$ 171,794 |
| Cephalon, Inc. | Pharmaceutical Manufacturer | \$ 2,150 | \$ - | \$ 2,150 |
| DermaRite Industries | Pharmaceutical Manufacturer | \$ 11,550 | \$ - | \$ 11,550 |
| Dey, L.P. | Pharmaceutical Manufacturer | \$ 7,150 | \$ - | \$ 7,150 |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 58,432 | \$ - | \$ 58,432 |
| Eli Lilly and Company | Pharmaceutical Manufacturer | \$ 16,300 | \$ - | \$ 16,300 |
| Esprit Pharma, Inc. | Pharmaceutical Manufacturer | \$ 1,950 | \$ - | \$ 1,950 |
| ETHEX Corp. | Pharmaceutical Manufacturer | \$ 31,547 | \$ - | \$ 31,547 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 235,963 | \$ - | \$ 235,963 |
| Genetco, Inc. | Pharmaceutical Manufacturer | \$ 5,520 | \$ - | \$ 5,520 |
| Geritrex Corporation | Pharmaceutical Manufacturer | \$ 3,650 | \$ - | \$ 3,650 |
| GlaxoSmithKline | Pharmaceutical Manufacturer | \$ 34,495 | \$ - | \$ 34,495 |
| Healthpoint, Ltd. | Pharmaceutical Manufacturer | \$ 6,100 | \$ - | \$ 6,100 |
| Hi-Tech Pharmacal | Pharmaceutical Manufacturer | \$ 8,041 | \$ - | \$ 8,041 |
| Janssen Pharmaceutica | Pharmaceutical Manufacturer | \$ 87,700 | \$ - | \$ 87,700 |
| Johnson & Johnson Health Care Systems, Inc. | Pharmaceutical Manufacturer | \$ 79,950 | \$ - | \$ 79,950 |
| Mallinckrodt, Inc. | Pharmaceutical Manufacturer | \$ 10,250 | \$ - | \$ 10,250 |
| Masters Pharmaceutical, Inc | Pharmaceutical Manufacturer | \$ 3,950 | \$ - | \$ 3,950 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 24,750 | \$ - | \$ 24,750 |
| Mission Pharmacal Company | Pharmaceutical Manufacturer | \$ 3,650 | \$ - | \$ 3,650 |
| Mylan Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 46,257 | \$ - | \$ 46,257 |
| Nomax, Inc | Pharmaceutical Manufacturer | \$ 3,100 | \$ - | \$ 3,100 |
| Novartis Pharmaceuticals Corporation | Pharmaceutical Manufacturer | \$ 7,600 | \$ - | \$ 7,600 |
| Novo Nordisk Inc. | Pharmaceutical Manufacturer | \$ 30,508 | \$ - | \$ 30,508 |
| Ortho Biotech | Pharmaceutical Manufacturer | \$ 40,604 | \$ - | \$ 40,604 |
| Ortho-McNeil Pharmaceuticals | Pharmaceutical Manufacturer | \$ 43,240 | \$ - | \$ 43,240 |
| Paddock Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 3,650 | \$ - | \$ 3,650 |
| Par Pharmaceuticals Companies, Inc. | Pharmaceutical Manufacturer | \$ 7,150 | \$ - | \$ 7,150 |
| Pfizer Inc. | Pharmaceutical Manufacturer | \$ 125,166 | \$ - | \$ 125,166 |
| Prasco Laboratories | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |
| Procter & Gamble Pharmaceuticals | Pharmaceutical Manufacturer | \$ 10,800 | \$ - | \$ 10,800 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 75,950 | \$ - | \$ 75,950 |
| SANTARUS, Inc. | Pharmaceutical Manufacturer | \$ 5,500 | \$ - | \$ 5,500 |

**American Society of Consultant Pharmacists
2007 Funding by Support Type**

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|--|-----------------------------|------------------------|-------------------------------|-------------------------|
| Schwarz Pharma, Inc. | Pharmaceutical Manufacturer | \$ 41,837 | \$ - | \$ 41,837 |
| Solvay Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 15,500 | \$ - | \$ 15,500 |
| Sucampo Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 25,650 | \$ - | \$ 25,650 |
| Takeda Pharmaceuticals North America, Inc. | Pharmaceutical Manufacturer | \$ 133,443 | \$ - | \$ 133,443 |
| TAP Pharmaceutical Products, Inc. | Pharmaceutical Manufacturer | \$ 32,695 | \$ - | \$ 32,695 |
| TEVA Pharmaceuticals USA | Pharmaceutical Manufacturer | \$ 9,750 | \$ - | \$ 9,750 |
| The Long Term Group: Johnson & Johnson Health Care | Pharmaceutical Manufacturer | \$ 103,550 | \$ - | \$ 103,550 |
| UCB Pharma, Inc. | Pharmaceutical Manufacturer | \$ 21,150 | \$ - | \$ 21,150 |
| UDL Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 8,450 | \$ - | \$ 8,450 |
| Upsher Smith Laboratories | Pharmaceutical Manufacturer | \$ 31,882 | \$ - | \$ 31,882 |
| Watson Pharma, Inc. | Pharmaceutical Manufacturer | \$ 11,700 | \$ - | \$ 11,700 |
| Wyeth | Pharmaceutical Manufacturer | \$ 109,523 | \$ - | \$ 109,523 |

| | | | |
|---------------------------------|--------------------|------------|--------------------|
| Total Commercial Support | \$2,043,315 | \$0 | \$2,043,315 |
|---------------------------------|--------------------|------------|--------------------|

| | | | | |
|---|----------------------------------|------------|------------|------------|
| Educational Support | | | | |
| Medical Communications Media, Inc. | Medical Education Communications | \$ 102,000 | \$ - | \$ 102,000 |
| Bristol-Myers Squibb Company | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 44,000 | \$ - | \$ 44,000 |
| GlaxoSmithKline | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| Healthpoint, Ltd. | Pharmaceutical Manufacturer | \$ 13,500 | \$ - | \$ 13,500 |
| Johnson & Johnson Health Care Systems, Inc. | Pharmaceutical Manufacturer | \$ 75,000 | \$ - | \$ 75,000 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 175,500 | \$ - | \$ 175,500 |
| Novo Nordisk Inc. | Pharmaceutical Manufacturer | \$ 153,381 | \$ 131,381 | \$ 22,000 |
| Ortho Biotech | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| Ortho-McNeil Pharmaceuticals | Pharmaceutical Manufacturer | \$ 34,500 | \$ - | \$ 34,500 |
| Procter & Gamble Pharmaceuticals | Pharmaceutical Manufacturer | \$ 11,000 | \$ - | \$ 11,000 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 146,000 | \$ - | \$ 146,000 |
| Sucampo Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 11,000 | \$ - | \$ 11,000 |
| Takeda Pharmaceuticals North America, Inc. | Pharmaceutical Manufacturer | \$ 51,740 | \$ - | \$ 51,740 |
| TAP Pharmaceutical Products, Inc. | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| Watson Pharma, Inc. | Pharmaceutical Manufacturer | \$ 194,400 | \$ 150,400 | \$ 44,000 |
| Wyeth | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |

| | | | |
|----------------------------------|--------------------|------------------|------------------|
| Total Educational Support | \$1,122,021 | \$281,781 | \$840,240 |
|----------------------------------|--------------------|------------------|------------------|

| | | | | |
|--------------------------------------|-----------------------------|-----------|----------|-----------|
| General Sponsorship Support | | | | |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 55,000 | \$ - | \$ 55,000 |
| Esprit Pharma, Inc. | Pharmaceutical Manufacturer | \$ 5,000 | \$ - | \$ 5,000 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 5,000 | \$ - | \$ 5,000 |
| Novartis Pharmaceuticals Corporation | Pharmaceutical Manufacturer | \$ 14,600 | \$ - | \$ 14,600 |
| Otsuka America Pharmaceutical, Inc. | Pharmaceutical Manufacturer | \$ 5,000 | \$ - | \$ 5,000 |
| Pfizer Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ 1,778 | \$ 222 |
| Procter & Gamble Pharmaceuticals | Pharmaceutical Manufacturer | \$ 4,500 | \$ 4,000 | \$ 500 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 65,628 | \$ - | \$ 65,628 |

| | | | |
|--|------------------|----------------|------------------|
| Total General Sponsorship Support | \$156,728 | \$5,778 | \$150,950 |
|--|------------------|----------------|------------------|

| | | | | |
|-------------------|-----------------------------|-----------|------|-----------|
| Consulting | | | | |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 45,000 | \$ - | \$ 45,000 |

**American Society of Consultant Pharmacists
2007 Funding by Support Type**

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|----------------------------------|-----------------------------|------------------------|-------------------------------|-------------------------|
| Eli Lilly and Company | Pharmaceutical Manufacturer | \$ 21,379 | \$ - | \$ 21,379 |
| Procter & Gamble Pharmaceuticals | Pharmaceutical Manufacturer | \$ 18,000 | \$ - | \$ 18,000 |

| | | | | |
|-------------------------|--|-----------------|------------|-----------------|
| Total Consulting | | \$84,379 | \$0 | \$84,379 |
|-------------------------|--|-----------------|------------|-----------------|

| | | | | |
|--|------------------------------|----------|------|----------|
| Dues | | | | |
| Apothecary Products, Inc. | Medical Equipment and Device | \$ 2,500 | \$ - | \$ 2,500 |
| Abbott Laboratories | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Amgen | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| AstraZeneca Pharmaceuticals LP | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 6,400 | \$ - | \$ 6,400 |
| E. Fougera & Company | Pharmaceutical Manufacturer | \$ 2,500 | \$ - | \$ 2,500 |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Eli Lilly and Company | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Esprit Pharma, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| GlaxoSmithKline | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| King Pharmaceuticals | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Mallinckrodt, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Novartis Pharmaceuticals Corporation | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Organon Pharmaceuticals USA Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Otsuka America Pharmaceutical Inc. | Pharmaceutical Manufacturer | \$ 1,200 | \$ - | \$ 1,200 |
| Par Pharmaceuticals Companies, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Pfizer Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Procter & Gamble Pharmaceuticals | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Purdue Pharma L.P. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Sucampo Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 1,200 | \$ - | \$ 1,200 |
| The Long Term Group: Johnson & Johnson Health Care | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| UCB Pharma, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| UDL Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Wyeth | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |

| | | | | |
|-------------------|--|------------------|------------|------------------|
| Total Dues | | \$132,600 | \$0 | \$132,600 |
|-------------------|--|------------------|------------|------------------|

| | | | | |
|----------------------|--|--------------------|------------------|--------------------|
| TOTAL SUPPORT | | \$3,539,042 | \$287,558 | \$3,251,484 |
|----------------------|--|--------------------|------------------|--------------------|

* ASCP was prime recipient of grant funds and payments were made to third-party partners as part of contractual obligation.

**American Society of Consultant Pharmacists
2008 Funding by Support Type**

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|---|----------------------------------|-----------------|------------------------|------------------|
| Commercial Support | | | | |
| WellPoint, Point of Sale Facilitated Enrollment | Insurance | \$ 3,500 | \$ - | \$ 3,500 |
| Assisted Living Consult/HealthCom Media | Medical Education Communications | \$ 1,775 | \$ - | \$ 1,775 |
| DesignWrite | Medical Education Communications | \$ 795 | \$ - | \$ 795 |
| HRA Research | Medical Education Communications | \$ 2,850 | \$ - | \$ 2,850 |
| Medical Communications Media | Medical Education Communications | \$ 2,385 | \$ - | \$ 2,385 |
| Accu - flo by Creative Strategies | Medical Equipment and Device | \$ 6,650 | \$ - | \$ 6,650 |
| WAVESENSE | Medical Equipment and Device | \$ 7,600 | \$ - | \$ 7,600 |
| Allergan, Inc. | Pharmaceutical Manufacturer | \$ 5,800 | \$ - | \$ 5,800 |
| Abbott Laboratories | Pharmaceutical Manufacturer | \$ 14,800 | \$ - | \$ 14,800 |
| Amgen | Pharmaceutical Manufacturer | \$ 25,132 | \$ - | \$ 25,132 |
| Anda, Inc. | Pharmaceutical Manufacturer | \$ 24,000 | \$ - | \$ 24,000 |
| Apotex Corp | Pharmaceutical Manufacturer | \$ 3,650 | \$ - | \$ 3,650 |
| Biocodex Inc. | Pharmaceutical Manufacturer | \$ 6,000 | \$ - | \$ 6,000 |
| Blair Laboratories / Dr. Tichenor's Antiseptic | Pharmaceutical Manufacturer | \$ 3,950 | \$ - | \$ 3,950 |
| Boehringer Ingelheim Pharmaceuticals, Inc | Pharmaceutical Manufacturer | \$ 102,800 | \$ - | \$ 102,800 |
| Breckenridge Pharmaceutical, Inc. | Pharmaceutical Manufacturer | \$ 2,850 | \$ - | \$ 2,850 |
| Bristol-Myers Squibb Company | Pharmaceutical Manufacturer | \$ 108,080 | \$ - | \$ 108,080 |
| Cubist Pharmaceuticals | Pharmaceutical Manufacturer | \$ 28,701 | \$ - | \$ 28,701 |
| DermaRite Industries | Pharmaceutical Manufacturer | \$ 9,800 | \$ - | \$ 9,800 |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 31,582 | \$ - | \$ 31,582 |
| Eli Lilly and Company | Pharmaceutical Manufacturer | \$ 235,755 | \$ - | \$ 235,755 |
| Endo Pharmaceuticals Inc. | Pharmaceutical Manufacturer | \$ 3,950 | \$ - | \$ 3,950 |
| ETHEX Corporation | Pharmaceutical Manufacturer | \$ 3,650 | \$ - | \$ 3,650 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 388,497 | \$ - | \$ 388,497 |
| Genetco, Inc. | Pharmaceutical Manufacturer | \$ 6,450 | \$ - | \$ 6,450 |
| GlaxoSmithKline | Pharmaceutical Manufacturer | \$ 60,200 | \$ - | \$ 60,200 |
| Healthpoint, Ltd. | Pharmaceutical Manufacturer | \$ 6,300 | \$ - | \$ 6,300 |
| Hi-Tech Pharmacal | Pharmaceutical Manufacturer | \$ 4,182 | \$ - | \$ 4,182 |
| HS Pharmaceuticals, LLC | Pharmaceutical Manufacturer | \$ 10,600 | \$ - | \$ 10,600 |
| Janssen Pharmaceutica | Pharmaceutical Manufacturer | \$ 12,500 | \$ - | \$ 12,500 |
| Johnson & Johnson Health Care Systems, Inc. | Pharmaceutical Manufacturer | \$ 114,600 | \$ - | \$ 114,600 |
| Mallinckrodt, Inc. | Pharmaceutical Manufacturer | \$ 10,900 | \$ - | \$ 10,900 |
| Masters Pharmaceutical, Inc | Pharmaceutical Manufacturer | \$ 4,950 | \$ - | \$ 4,950 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 14,700 | \$ - | \$ 14,700 |
| Mission Pharmacal Company | Pharmaceutical Manufacturer | \$ 3,650 | \$ - | \$ 3,650 |
| Mylan Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 52,156 | \$ - | \$ 52,156 |
| Novartis Pharmaceuticals Corporation | Pharmaceutical Manufacturer | \$ 23,400 | \$ - | \$ 23,400 |
| Novo Nordisk Inc. | Pharmaceutical Manufacturer | \$ 15,482 | \$ - | \$ 15,482 |
| Ortho Biotech | Pharmaceutical Manufacturer | \$ 34,000 | \$ - | \$ 34,000 |
| Paddock Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 3,650 | \$ - | \$ 3,650 |
| Pamlab, LLC | Pharmaceutical Manufacturer | \$ 6,000 | \$ - | \$ 6,000 |
| Par Pharmaceuticals Companies, Inc. | Pharmaceutical Manufacturer | \$ 7,150 | \$ - | \$ 7,150 |
| Pfizer Inc. | Pharmaceutical Manufacturer | \$ 96,742 | \$ - | \$ 96,742 |
| Prasco Laboratories | Pharmaceutical Manufacturer | \$ 2,500 | \$ - | \$ 2,500 |
| Procter and Gamble Pharmaceuticals | Pharmaceutical Manufacturer | \$ 28,100 | \$ - | \$ 28,100 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 73,200 | \$ - | \$ 73,200 |
| SANTARUS, Inc. | Pharmaceutical Manufacturer | \$ 19,800 | \$ - | \$ 19,800 |
| Sucampo Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 9,750 | \$ - | \$ 9,750 |
| Takeda Pharmaceuticals North America, Inc. | Pharmaceutical Manufacturer | \$ 94,646 | \$ - | \$ 94,646 |

**American Society of Consultant Pharmacists
2008 Funding by Support Type**

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|--|-----------------------------|-----------------|------------------------|------------------|
| TAP Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 9,000 | \$ - | \$ 9,000 |
| TEVA Pharmaceutical | Pharmaceutical Manufacturer | \$ 7,600 | \$ - | \$ 7,600 |
| The Long Term Group: Johnson & Johnson Health Care | Pharmaceutical Manufacturer | \$ 19,800 | \$ - | \$ 19,800 |
| TOP RX, Inc | Pharmaceutical Manufacturer | \$ 2,850 | \$ - | \$ 2,850 |
| UCB Pharma, Inc. | Pharmaceutical Manufacturer | \$ 48,716 | \$ - | \$ 48,716 |
| UDL Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 5,600 | \$ - | \$ 5,600 |
| Upsher-Smith Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 7,150 | \$ - | \$ 7,150 |
| Watson Pharma, Inc. | Pharmaceutical Manufacturer | \$ 13,150 | \$ - | \$ 13,150 |
| Wyeth | Pharmaceutical Manufacturer | \$ 140,067 | \$ - | \$ 140,067 |

| | | | | |
|---------------------------------|--|--------------------|------------|--------------------|
| Total Commercial Support | | \$1,994,093 | \$0 | \$1,994,093 |
|---------------------------------|--|--------------------|------------|--------------------|

| | | | | |
|------------------------------|-----------------------------|----------|------|----------|
| Consulting Support | | | | |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 2,000 | \$ - | \$ 2,000 |

| | | | | |
|---------------------------------|--|----------------|------------|----------------|
| Total Consulting Support | | \$2,000 | \$0 | \$2,000 |
|---------------------------------|--|----------------|------------|----------------|

| | | | | |
|---|------------------------------|----------|------|----------|
| Dues | | | | |
| Apothecary Products, Inc. | Medical Equipment and Device | \$ 2,500 | \$ - | \$ 2,500 |
| Abbott Laboratories | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Allergan, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Amgen | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| AstraZeneca Pharmaceuticals | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Boehringer Ingelheim Pharmaceuticals, Inc | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Eli Lilly and Company | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Fougera | Pharmaceutical Manufacturer | \$ 2,500 | \$ - | \$ 2,500 |
| GlaxoSmithKline | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Mallinckrodt, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Otsuka America Pharmaceutical, Inc | Pharmaceutical Manufacturer | \$ 1,200 | \$ - | \$ 1,200 |
| Procter and Gamble Pharmaceuticals | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Purdue Pharma LP | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Sucampo Pharmaceuticals, Inc | Pharmaceutical Manufacturer | \$ 1,200 | \$ - | \$ 1,200 |
| UCB Pharma, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| UDL Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Wyeth | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |

| | | | | |
|-------------------|--|-----------------|------------|-----------------|
| Total Dues | | \$99,200 | \$0 | \$99,200 |
|-------------------|--|-----------------|------------|-----------------|

| | | | | |
|---|----------------------------------|------------|-----------|------------|
| Educational Support | | | | |
| Medical Communications Media, Inc. | Medical Education Communications | \$ 56,500 | \$ - | \$ 56,500 |
| Amgen | Pharmaceutical Manufacturer | \$ 48,875 | \$ 30,375 | \$ 18,500 |
| Bristol-Myers Squibb Company | Pharmaceutical Manufacturer | \$ 23,500 | \$ - | \$ 23,500 |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 10,000 | \$ - | \$ 10,000 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 23,500 | \$ - | \$ 23,500 |
| Johnson & Johnson Health Care Systems, Inc. | Pharmaceutical Manufacturer | \$ 100,000 | \$ - | \$ 100,000 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 52,500 | \$ - | \$ 52,500 |

**American Society of Consultant Pharmacists
2008 Funding by Support Type**

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|--|-----------------------------|--------------------|------------------------|--------------------|
| Novo Nordisk Inc. | Pharmaceutical Manufacturer | \$ 212,484 | \$ 142,984 | \$ 69,500 |
| Ortho Biotech | Pharmaceutical Manufacturer | \$ 67,000 | \$ - | \$ 67,000 |
| Ortho-McNeil Pharmaceuticals | Pharmaceutical Manufacturer | \$ 18,500 | \$ - | \$ 18,500 |
| Pfizer Inc. | Pharmaceutical Manufacturer | \$ 482,440 | \$ 440,940 | \$ 41,500 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 42,000 | \$ - | \$ 42,000 |
| Takeda Pharmaceuticals North America, Inc. | Pharmaceutical Manufacturer | \$ 1,822,327 | \$ 1,564,739 | \$ 257,588 |
| TAP Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 22,000 | \$ - | \$ 22,000 |
| UCB Pharma, Inc. | Pharmaceutical Manufacturer | \$ 23,500 | \$ - | \$ 23,500 |
| Total Educational Support | | \$3,005,126 | \$2,179,038 | \$826,088 |
| General Sponsorship Support | | | | |
| Amgen | Pharmaceutical Manufacturer | \$ 15,575 | \$ - | \$ 15,575 |
| Boehringer Ingelheim Pharmaceuticals, Inc | Pharmaceutical Manufacturer | \$ 6,000 | \$ - | \$ 6,000 |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 25,000 | \$ - | \$ 25,000 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 10,000 | \$ - | \$ 10,000 |
| Total General Sponsorship Support | | \$56,575 | \$0 | \$56,575 |
| TOTAL SUPPORT | | \$5,156,994 | \$2,179,038 | \$2,977,956 |

* ASCP was prime recipient of grant funds and payments were made to third-party partners as part of contractual obligation.

**American Society of Consultant Pharmacists
2009 Funding by Support Type**

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|---|------------------------------|-----------------|------------------------|------------------|
| Commercial Support | | | | |
| Abbott Laboratories | Pharmaceutical Manufacturer | \$ 16,500 | \$ - | \$ 16,500 |
| Accu - flo by Creative Strategies | Medical Equipment and Device | \$ 6,500 | \$ - | \$ 6,500 |
| Amerifit Brands | Pharmaceutical Manufacturer | \$ 3,900 | \$ - | \$ 3,900 |
| Amgen | Pharmaceutical Manufacturer | \$ 38,312 | \$ - | \$ 38,312 |
| Anda, Inc. | Pharmaceutical Manufacturer | \$ 24,800 | \$ - | \$ 24,800 |
| ASHP Advantage | Medical Education Companies | \$ 4,412 | \$ - | \$ 4,412 |
| Astellas Pharma US, Inc | Pharmaceutical Manufacturer | \$ 3,900 | \$ - | \$ 3,900 |
| AstraZeneca | Pharmaceutical Manufacturer | \$ 54,341 | \$ - | \$ 54,341 |
| Biocodex Inc. | Pharmaceutical Manufacturer | \$ 6,200 | \$ - | \$ 6,200 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 62,150 | \$ - | \$ 62,150 |
| Breckenridge Pharmaceutical, Inc. | Pharmaceutical Manufacturer | \$ 2,950 | \$ - | \$ 2,950 |
| Covidien-Mallinckrodt | Pharmaceutical Manufacturer | \$ 5,800 | \$ - | \$ 5,800 |
| Cubist Pharmaceuticals | Pharmaceutical Manufacturer | \$ 39,324 | \$ - | \$ 39,324 |
| Dey, L.P. | Pharmaceutical Manufacturer | \$ 10,550 | \$ - | \$ 10,550 |
| Eisai Inc. | Pharmaceutical Manufacturer | \$ 28,400 | \$ - | \$ 28,400 |
| Eli Lilly and Company | Pharmaceutical Manufacturer | \$ 68,950 | \$ - | \$ 68,950 |
| Endo Pharmaceuticals Inc. | Pharmaceutical Manufacturer | \$ 4,050 | \$ - | \$ 4,050 |
| Eurand Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 3,200 | \$ - | \$ 3,200 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 184,864 | \$ - | \$ 184,864 |
| Genetco, Inc. | Pharmaceutical Manufacturer | \$ 6,100 | \$ - | \$ 6,100 |
| GlaxoSmithKline | Pharmaceutical Manufacturer | \$ 57,250 | \$ - | \$ 57,250 |
| Healthpoint, Ltd. | Pharmaceutical Manufacturer | \$ 3,750 | \$ - | \$ 3,750 |
| Hi-Tech Pharmacal | Pharmaceutical Manufacturer | \$ 8,614 | \$ - | \$ 8,614 |
| HS Pharmaceuticals, LLC | Pharmaceutical Manufacturer | \$ 2,750 | \$ - | \$ 2,750 |
| Johnson & Johnson Health Care Systems, Inc. | Pharmaceutical Manufacturer | \$ 89,600 | \$ - | \$ 89,600 |
| Masters Pharmaceutical, Inc | Pharmaceutical Manufacturer | \$ 5,000 | \$ - | \$ 5,000 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 40,955 | \$ - | \$ 40,955 |
| Mylan Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 48,631 | \$ - | \$ 48,631 |
| Novartis Pharmaceuticals Corporation | Pharmaceutical Manufacturer | \$ 12,000 | \$ - | \$ 12,000 |
| Novo Nordisk Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 55,250 | \$ - | \$ 55,250 |
| Ortho-McNeil Pharmaceuticals | Pharmaceutical Manufacturer | \$ 20,274 | \$ - | \$ 20,274 |
| Paddock Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 3,375 | \$ - | \$ 3,375 |
| Pamlab, LLC | Pharmaceutical Manufacturer | \$ 6,700 | \$ - | \$ 6,700 |
| Pfizer Inc. | Pharmaceutical Manufacturer | \$ 77,506 | \$ - | \$ 77,506 |
| PriCara | Pharmaceutical Manufacturer | \$ 21,651 | \$ - | \$ 21,651 |
| Procter & Gamble Pharmaceuticals | Pharmaceutical Manufacturer | \$ 5,650 | \$ - | \$ 5,650 |
| Roche | Pharmaceutical Manufacturer | \$ 18,750 | \$ - | \$ 18,750 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 110,713 | \$ - | \$ 110,713 |
| Stevens, Blair & Company | Medical Education Companies | \$ 2,600 | \$ - | \$ 2,600 |
| Sucampo Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 5,850 | \$ - | \$ 5,850 |
| Takeda Pharmaceuticals North America, Inc. | Pharmaceutical Manufacturer | \$ 11,532 | \$ - | \$ 11,532 |
| TEVAPharmaceuticals USA | Pharmaceutical Manufacturer | \$ 7,200 | \$ - | \$ 7,200 |
| TOP RX, Inc | Pharmaceutical Manufacturer | \$ 2,600 | \$ - | \$ 2,600 |
| UCB Pharma, Inc. | Pharmaceutical Manufacturer | \$ 64,451 | \$ - | \$ 64,451 |
| UDL Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 5,800 | \$ - | \$ 5,800 |
| Upsher-Smith Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 7,350 | \$ - | \$ 7,350 |
| Victory Pharma | Pharmaceutical Manufacturer | \$ 3,900 | \$ - | \$ 3,900 |
| Watson Pharma, Inc. | Pharmaceutical Manufacturer | \$ 13,550 | \$ - | \$ 13,550 |
| Wyeth | Pharmaceutical Manufacturer | \$ 110,557 | \$ - | \$ 110,557 |

**American Society of Consultant Pharmacists
2009 Funding by Support Type**

| Company Name | Company Type | Amount Received | Third-Party Payments * | ASCP Net Revenue |
|--------------|--------------|-----------------|------------------------|------------------|
|--------------|--------------|-----------------|------------------------|------------------|

| | | | | |
|---------------------------------|--|--------------------|------------|--------------------|
| Total Commercial Support | | \$1,399,012 | \$0 | \$1,399,012 |
|---------------------------------|--|--------------------|------------|--------------------|

| | | | | |
|---|----------------------------------|------------|------------|------------|
| Educational Support | | | | |
| Medical Communications Media, Inc. | Medical Education Communications | \$ 62,750 | \$ - | \$ 62,750 |
| Astellas Pharma US, Inc | Pharmaceutical Manufacturer | \$ 23,000 | \$ - | \$ 23,000 |
| Endo Pharmaceuticals | Pharmaceutical Manufacturer | \$ 10,000 | \$ - | \$ 10,000 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 46,500 | \$ - | \$ 46,500 |
| Johnson & Johnson Health Care Systems, Inc. | Pharmaceutical Manufacturer | \$ 100,000 | \$ - | \$ 100,000 |
| Merck & Co., Inc. | Pharmaceutical Manufacturer | \$ 7,500 | \$ - | \$ 7,500 |
| Novo Nordisk Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 219,530 | \$ 153,030 | \$ 66,500 |
| Ortho-McNeil Pharmaceuticals | Pharmaceutical Manufacturer | \$ 43,500 | \$ - | \$ 43,500 |
| sanofi-aventis | Pharmaceutical Manufacturer | \$ 23,000 | \$ - | \$ 23,000 |
| Takeda Pharmaceuticals North America, Inc. | Pharmaceutical Manufacturer | \$ 600,504 | \$ 521,004 | \$ 79,500 |

| | | | | |
|----------------------------------|--|--------------------|------------------|------------------|
| Total Educational Support | | \$1,136,284 | \$674,034 | \$462,250 |
|----------------------------------|--|--------------------|------------------|------------------|

| | | | | |
|------------------------------------|-----------------------------|-----------|------|-----------|
| General Sponsorship Support | | | | |
| Amgen | Pharmaceutical Manufacturer | \$ 15,757 | \$ - | \$ 15,757 |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 45,000 | \$ - | \$ 45,000 |

| | | | | |
|--|--|-----------------|------------|-----------------|
| Total General Sponsorship Support | | \$60,757 | \$0 | \$60,757 |
|--|--|-----------------|------------|-----------------|

| | | | | |
|---|------------------------------|----------|------|----------|
| Dues | | | | |
| Amgen | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Apothecary Products, Inc. | Medical Equipment and Device | \$ 2,500 | \$ - | \$ 2,500 |
| Boehringer Ingelheim Pharmaceuticals Inc. | Pharmaceutical Manufacturer | \$ 6,100 | \$ - | \$ 6,100 |
| Eisai, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Eli Lilly and Company | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Forest Pharmaceuticals, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Fougera | Pharmaceutical Manufacturer | \$ 2,500 | \$ - | \$ 2,500 |
| GlaxoSmithKline | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Mallinckrodt, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| Purdue Pharma LP | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |
| UDL Laboratories, Inc. | Pharmaceutical Manufacturer | \$ 5,400 | \$ - | \$ 5,400 |

| | | | | |
|-------------------|--|-----------------|------------|-----------------|
| Total Dues | | \$54,300 | \$0 | \$54,300 |
|-------------------|--|-----------------|------------|-----------------|

| | | | | |
|----------------------|--|--------------------|------------------|--------------------|
| TOTAL SUPPORT | | \$2,650,353 | \$674,034 | \$1,976,319 |
|----------------------|--|--------------------|------------------|--------------------|

* ASCP was prime recipient of grant funds and payments were made to third-party partners as part of contractual obligation.